🚀 VC round data is live in beta, check it out!
Liminatus Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Liminatus Pharma and similar public comparables like ODI Pharma, Gelteq, Pure Biologics, Spago Nanomedical and more.
Liminatus Pharma Overview
About Liminatus Pharma
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.
Founded
N/A
HQ
Employees
N/A
Website
N/A
Sectors
Financials (FY)
EV
$9M
Liminatus Pharma Financials
Liminatus Pharma reported last fiscal year revenue of — and negative EBITDA of ($5M).
In the same fiscal year, Liminatus Pharma generated ($5M) in EBITDA losses and had net loss of ($5M).
Liminatus Pharma P&L
In the most recent fiscal year, Liminatus Pharma reported revenue of — and EBITDA of ($5M).
Liminatus Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($5M) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($5M) | XXX | XXX | XXX |
| Net Debt | — | — | $16M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Liminatus Pharma Stock Performance
Liminatus Pharma has current market cap of $8M, and enterprise value of $9M.
Market Cap Evolution
Liminatus Pharma's stock price is $0.25.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9M | $8M | 0.0% | XXX | XXX | XXX | $-0.16 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLiminatus Pharma Valuation Multiples
Liminatus Pharma trades at (1.8x) EV/EBITDA.
Liminatus Pharma Financial Valuation Multiples
As of March 30, 2026, Liminatus Pharma has market cap of $8M and EV of $9M.
Equity research analysts estimate Liminatus Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Liminatus Pharma has a P/E ratio of (1.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8M | XXX | $8M | XXX | XXX | XXX |
| EV (current) | $9M | XXX | $9M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.8x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (1.8x) | XXX | XXX | XXX |
| P/E | — | XXX | (1.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (2.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Liminatus Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Liminatus Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| ODI Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Gelteq | XXX | XXX | XXX | XXX | XXX | XXX |
| Pure Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Spago Nanomedical | XXX | XXX | XXX | XXX | XXX | XXX |
| TME Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Liminatus Pharma M&A Activity
Liminatus Pharma acquired XXX companies to date.
Last acquisition by Liminatus Pharma was on XXXXXXXX, XXXXX. Liminatus Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Liminatus Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLiminatus Pharma Investment Activity
Liminatus Pharma invested in XXX companies to date.
Liminatus Pharma made its latest investment on XXXXXXXX, XXXXX. Liminatus Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Liminatus Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Liminatus Pharma
| Where is Liminatus Pharma headquartered? | Liminatus Pharma is headquartered in United States. |
| Who is the CEO of Liminatus Pharma? | Liminatus Pharma's CEO is Chris Kim. |
| Is Liminatus Pharma publicly listed? | Yes, Liminatus Pharma is a public company listed on Nasdaq. |
| What is the stock symbol of Liminatus Pharma? | Liminatus Pharma trades under LIMN ticker. |
| When did Liminatus Pharma go public? | Liminatus Pharma went public in 2025. |
| Who are competitors of Liminatus Pharma? | Liminatus Pharma main competitors are ODI Pharma, Gelteq, Pure Biologics, Spago Nanomedical. |
| What is the current market cap of Liminatus Pharma? | Liminatus Pharma's current market cap is $8M. |
| Is Liminatus Pharma profitable? | No, Liminatus Pharma is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.